

Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study

Irene Moreno, Tatiana Hernández, Emiliano Calvo, Salvador Fudio, Carmen Kahatt, Cristian Fernández, Jorge Luis Iglesias, Gema Corral, Laura Pérez-Ramos, Lola Montilla, Ali Zeaiter and Rubin Lubomirov.

Supplementary material




Figure S1. Schematic diagram of trial design. Note: in Sequence 2 (RT) the Day 15 (D15) of Cycle 1 and the Day –6 (D–6) of Cycle 2 represent the same day/visit in the absence of delays. Patients were randomized to receive either Sequence 1 (TR) of bosentan with lurbinectedin in Cycle 1 followed by two consecutive cycles of lurbinectedin alone [last cycle being optional] or Sequence 2 (RT) of lurbinectedin alone in Cycle 1, bosentan with lurbinectedin in Cycle 2 and lurbinectedin alone in Cycle 3 (optional).